Treatment of MDR TB requires regular administration of second line drugs for up to two years - a severe burden on both patients and healthcare systems in the low-income areas where TB is most prevalent. There are only a limited number of hospitals that can provide the care needed for MDR TB patients, who require hospitalization. Better treatment options for MDR TB are urgently needed.

Which are the new TB-related projects in the pipeline?
Tibotec is committed to fighting TB and has a discovery research program with the Global TB Alliance to identify new compounds for the treatment of TB. A new compound TMC207 is in phase II clinical trials in patients with multi-drug-resistant TB (MDR TB) in combination with other second line TB drugs.

Our goal is to accelerate development and approval of TMC207 as part of a new regimen for the treatment of MDR TB. Recognizing that new, faster and better TB drugs will only be effective if they are affordable and available, Tibotec and its future partners will work with global, regional, and national stakeholders to ensure regulatory approval, adoption by TB programs, and widespread availability of new drug regimens.